ArticleClinical and experimental medicine2025
Potential prognostic biomarker MIER2 in colon adenocarcinoma: from data mining to validation.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bioinformatics and experimental approach identifies glycoprotein-based diagnostic and prognostic biomarkers for colon adenocarcinoma.Scientific reports · 2026Article
- Integrated Molecular and Functional Characterization of Cervical Small-Cell Neuroendocrine Carcinoma Using a 3D Organoid Model.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon adenocarcinoma (COAD) is highly malignant tumor in the gastrointestinal tract, and reliable biomarkers for predicting its prognosis are remain lacking. MIER Family Member 2 (MIER2) has been implicated in tumor biology, yet its role in COAD remains unclear. MIER2 expression in COAD was analyzed using TCGA and UALCAN databases. Survival analysis, Cox regression, and nomogram construction were performed to evaluate its prognostic value. Functional enrichment analysis was conducted via LinkedOmics. Immune infiltration was assessed using ESTIMATE and CIBERSORT algorithms. Additionally, the effect of MIER2knockdown on the proliferation, and migration of SW480 cell was evaluated. The expression of MIER2 was significantly higher in COAD tissues and associated with a poorer OS, DSS and PFI. Multivariate analysis confirmed MIER2 as an independent prognostic factor. Co-expressed gene analysis revealed enrichment in immune-related pathways, including type I interferon signaling and macrophage activation. In addition, MIER2 expression was associated with altered immune infiltration. MIER2 knockdown suppressed SW480 cell proliferation and migration, and RNA-seq further indicated that this might be related to the intrinsic apoptotic signaling pathway. High expression of MIER2 is associated with poor prognosis and immune cell infiltration, and it serve as a novel prognostic biomarker and potential therapeutic target for COAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.